Gemcitabine news

All news on Gemcitabine (also known as Gemzar): plants, production capacities, investments and involved companies.

29 June 2026

Genmab: EPCORE DLBCL-4 shows PFS benefit for epcoritamab plus lenalidomide

Phase 3 topline: fixed‑duration subcutaneous epcoritamab + lenalidomide significantly reduced progression/death versus R‑GemOx in relapsed/refractory DLBCL; safety consistent with known profiles.
18 June 2026

Roche: FDA accepts sBLA for subcutaneous Lunsumio VELO plus Polivy in relapsed/refractory LBCL

sBLA accepted based on phase III SUNMO showing 59% reduction in progression risk; FDA decision expected by 9 Feb 2027.
17 June 2026

Genentech seeks FDA approval for Lunsumio VELO plus Polivy in relapsed/refractory LBCL

sBLA accepted for subcutaneous bispecific + ADC combo in relapsed/refractory large B‑cell lymphoma; FDA decision expected Feb 9, 2027.
23 March 2026

Chugai obtains MHLW approval for Lunsumio–Polivy combo in relapsed/refractory large B‑cell lymphoma

Japan approves Lunsumio + Polivy for relapsed/refractory large B‑cell lymphoma after Phase III SUNMO: ORR 69.7%, PFS 11.5 vs 3.8 months (59% lower progression/death risk); manageable safety.
16 January 2026

Genmab Reports Phase 3 Trial Results for Epcoritamab in Relapsed/Refractory DLBCL

Epcoritamab shows improved progression-free survival in Phase 3 trial for R/R DLBCL. Safety profile consistent. Further analysis and regulatory discussions planned.
8 December 2025

Roche's Columvi Combo Shows Sustained Survival Benefit in Phase III Study

Columvi with GemOx doubles survival in R/R DLBCL patients, approved in 50+ countries, offering a non-transplant treatment option.

Who will be producing Gemcitabine in the future?

Find out with chemXplore Alpha

Learn more